|
The unique grouping of fatty acids in Lyprinol has evolved as the most potent group of Omega-3 lipids in blocking the 5 - lipoxygenase metabolic pathway responsible for inflammation in the body.
Inflammopharmacology, Vol. 0, No. 0, pp. 1-17 (1999):Over the counter (OTC) oral remedies for arthritis and rheumatism: how effective are they? M.W. Whitehouse.
This unique marine product has been exposed to critical review by many research institutions world wide and is proven to have significant anti-inflammatory activity in vitro in inhibiting leukotriene synthesis and in vivo by markedly reducing the severity of adjuvant-induced poly arthritis in rat models. Various publications have been released confirming these results all of which are available on request. Leukotrienes are formed in the body via the lipoxygenase pathway and are responsible for initiating and extending the inflammatory process. The work carried out in The Queen Elizabeth Hospital and the University of Adelaide in Australia and the Charite University in Berlin, Germany has clearly demonstrated that the stabilised marine lipid Lyprinol® is a powerful modulator of the 5-lipoxygenase pathway, thus its ability to markedly reduce the damaging effects of persistent inflammation that one may find in various allergic reactions including arthritis and other inflammatory disorders including inflammation of the respiratory airways. Since many of the currently used anti-inflammatory drugs, in particular the non-steroid anti-inflammatory drugs (NSAID), function via the cyclo-oxygenase pathway, much recent international research and effort has gone into the development of modulators of the second major pathway, the lipoxygenase pathway.
There is little doubt that Lyprinol® can provide a potent means of controlling and inhibiting the damage caused by the excesses of the body's inflammatory responses. In vivo studies undertaken at The University of Queensland in Australia tested the anti-arthritic properties of Lyprinol®. Using the standard model for evaluating the potency of anti-arthritic drugs, Lyprinol® was measured against its ability to reduce the swelling which occurs in adjuvant induced poly arthritis in rats. Published in the Journal "Inflammopharmacology". The results were dramatic, with Lyprinol® reducing joint swelling by 93% compared with untreated controls. Following these outstanding findings The University of Queensland scientists set out to compare Lyprinol® with two widely used anti-arthritic drugs, namely Indomethacin & Ibuprofen. When given orally at the same dose rate (5mg/kg body wt./day) Lyprinol® outperformed the drugs Indomethacin & Ibuprofen by a factor of 2:1. This was a staggeringly successful outcome for Lyprinol®. More recently a double blind clinical trial conducted at the Hong Kong Poly Tech University has shown that the patients taking Lyprinol had greater improvement in the perception of pain as measured by the VAS, and patients’ global assessment of arthritis in those who took Lyprinol® when compared with controls from week 4 following adjustment for the change in the amount of paracetamol used between study visits. Patients who took Lyprinol® but not placebo also had improved scores in the CAIMS2-SF physical function and psychological status domains from week 4*. The results from this paper have been published in the journal ‘PROGRESS IN NUTRITION VOL. 6, N. 1, 17-31, 2004’
Lyprinol has also been trialed for the use in mild to moderate asthmatics as an adjuvant treatment. In a study conducted at the Pavlov Medical University St Petersburg, Russia there was a significant decrease in daytime wheeze, the concentration of exhaled H2O2 and an increase in morning PEF in the lipid extract group compared to the placebo group. The results of this clinical trial were published in ‘The European Respiratory Journal 2002; 20: 596–600’.
Note: Much more research has been conducted on Lyprinol over the past 25 years, all of which is available on request.
Anti-inflammatories
The process of inflammation is highly complex and is defined as the body's reaction to physical, chemical or biological injury which, in a normal healthy individual, results in the localization of the problem and regeneration or repair of the damaged tissue.
Unfortunately, inflammatory response is not always beneficial to the individual.A prime example is that of osteoarthritis, an inflammatory disease which can effect all the bone joints of the human body but primarily affects the "wear and tear" joints of the feet, knees, hands, hips, shoulders, elbows and back which have usually had the effects of many years of work and sometimes injury. In certain circumstances, the process itself can cause damage and injury. The auto-immune disease, rheumatoid arthritis, where the body attacks itself, and the hypersensitive states leading to asthma and anaphylactic shock, are examples of uncontrolled inflammatory responses.
Initiation and control of the inflammatory process is complex and governed by an array of biomolecular mechanisms. One important pro-inflammatory mechanism is closely associated with cell-membrane bound arachidonic acid, which becomes converted into other compounds in the body which are potent inflammation-supporting substances.
This occurs by two major pathways in our metabolism:
Many of the products of these pathways have potent inflammation-supporting properties. For instance, LTB 4 is a potent chemotactic agent capable of attracting large numbers of leucocytes (white blood cells), to the site of the injury. LTC 4, LTD 4, and LTE 4, which are metabolites of LTB 4, are potent bronchoconstricting agents and were formerly identified as SRS-A's (slow reacting substance of anaphylaxis), a key factor in anaphylactic shock.Currently used anti-inflammatory drugs function mainly by inhibiting the cyclo-oxygenase pathway. In view of the important functions of the inflammatory process ascribed to the lipoxygenase pathway, there has been considerable scientific effort to develop a 5-lipoxygenase pathway inhibitor over the past decade. Lyprinol® is a 5-lipoxygenase pathway modulator which is both effective and safe.
Structure of Lyprinol
Lyprinol® is a mixture of five main lipid classes including sterol esters, triglycerides, free fatty acids, sterols and polar lipids. There are approximately 8-10 different marine sterols in the sterol esters and sterol fractions. It also contains more than 30 different essential fatty acids which are mixtures of saturated, monounsaturated and polyunsaturated fatty acids.
Lyprinol® is a source of long chain omega-3 polyunsaturated fatty acids which are essential for health in humans. The two main omega-3 PUFA's present in Lyprinol® are eicosapentaenoic acid (20 carbons and 5 double bonds, shorthand =20:5 omega-3) (EPA) and docosahexaenoic acid (22:6 omega-3) (DHA).
It also contains several other fatty acids which belong to the omega-3 PUFA family. These fatty acids all have four double bonds and have carbon chain lengths of 18, 19 and 20 carbon atoms, respectively, thus they are described as 18:4 omega-3 (18:4n-3), 19:4 omega-3 and 20:4 omega-3 (ETA).
Natural arthritis relief
Studies using Lyprinol® have shown positive results in relieving arthritic conditions by modulation of the principal human inflammatory pathway known as "the lipoxygenase pathway".
The lipoxygenase pathway has been long recognised by researchers as the major pathway of operation for many inflammatory diseases and subsequently scientists have been searching for a lipoxygenase pathway inhibitor for the past two decades. Several synthetic inhibitors have been developed but all have harmful side effects for humans.
Lyprinol® is derived from a food source and is the first effective naturally occuring lipoxygenase pathway modulator which is safe for human consumption.
History of Lyprinol
The Perna canalicula mussel possesses a profile of Omega-3 essential fatty acids which are unique to its species. The presence of this rich source of essential fatty acids provides the mussel with potent anti-inflammatory activity. This can be passed on to consumers only when the mussel is consumed fresh and raw. In its natural state the mussel thrives in coastal areas where there is a constant flow of ocean current. The mussel acts as a kind of filtration system extracting nutrients from the fresh sea water and dispelling the waste.
In 1970 a major research project was underway in the USA to discover a cure for various diseases and the scientists involved were screening shellfish from around the world including New Zealand Perna canalicula Mussel. Following this, considerable research began in order to verify that the mussel had anti-inflammatory activity.
Early study results were erratic and no consistent results could be determined. Naturally the sceptics were quick to slander the anti-inflammatory potential of the mussels. What the early researchers failed to realise was that the coastal Maoris ate the mussels fresh from the ocean and any other processing procedure like extreme heat, freeze drying and refrigeration without a stabilisation or anti-oxygenation process would promote oxidation of the active components, therefore dramatically lessening the mussel's potency.
This soon became the focal point for a research project to develop a method to stabilise the mussel meat and as a result, a patented process was developed. However, this procedure relies heavily on the freshness of the mussel meat. Therefore harvesting must be closely coordinated directly with the processing plant. The Perna canalicula mussel today is farmed commercially in New Zealand principally for the international food market. However, the percentage allocated to the development of therapeutic/nutriceuticals market is growing.
The Royal Melbourne Institute of Technology University in Australia (RMIT University) has recently completed 15 years of research into isolating the active lipids within the mussel. Headed initially by internationally renowned bio-medical research scientist Professor Robert Borland, the project has produced a remarkably potent compound named "Lyprinol®".
Natural anti-inflammatories
Lyprinol is a powerful natural pain reliever that provides relief for joint pain and arthritis, promotes healthy breathing passages, and can potentially increase brain function. Lyprinol acts by normalizing inflammation in swelling joints and the body’s airways, making moving and breathing easier.
Lyprinol, a superior type of marine oil gaining popularity worldwide, is touted as the all-around health aid for various inflammatory disorders.
Offering a combination of omega 3 and omega 6 marine lipids, as well as some unique compounds, the potency of Lyprinol is also much greater than the highest quality of fish oils. As a result, one Lyprinol capsule has about the same degree of benefits as a jar of fish oil capsules.
A product from the sea
Following fifteen years of international scientific research by independent scientists from the Royal Melbourne Institute of Technology University, the goal of identifying the principal components responsible for the extract's high potency was achieved. The compounds were patented and trademarked, PCSO-524™ which is then formulated in to the product Lyprinol®.
Most mussel powders over the years have shown conflicting results in efficacy studies due to the oxidation of their non-polar lipids (PCSO-524™) which is where their true activity lies. A patent was granted for the stabilisation of the mussel powder and also for the extraction process for PCSO-524®. Usage patents are also in place for its anti-inflammatory efficacy and other exciting applications for the formulated product Lyprinol®.
Marine Complex Lyprinol® is the formulated product containing the unique patented marine lipid group comprising a unique combination of different non-polar lipid groups and Omega-3 polyunsaturated fatty acids which are extracted from the New Zealand Green-Lipped Mussel (Perna canaliculus) along with pharmaceutical grade olive oil and d-alpha-tocopherol (vitamin E).
Many scientists and government institutions around the world agree that the average western diet is very high in another group of fatty acids, namely Omega-6's. As a result our cell membranes are unusually rich in precursors associated with inflammatory processes which can lead to arthritis, psoriasis and asthma, to name a few.
What is PCSO-524®?
PCSO-524® is the name given to the active component of the Lyprinol® formulation. PCSO-524® contains 92 fatty acids and is what gives Lyprinol® its potent anti-inflammatory action. PCSO-524® is the result of decades of research and development and has been shown in numerous published trials to be a powerful natural anti-inflammatory for which there are no known adverse side effects*. Lyprinol® contains 50mg of PCSO-524®, 100mg of a proprietary oleic acid blend and 0.225mg of d-alpha-tocopherol (natural vitamin E).
Arthritis relieved
Published peer-reviewed trials have show that Lyprinol® is able to relieve the inflammation and pain that are associated with arthritis, by modulating the main inflammatory pathway, which is known as the lipoxygenase pathway*. PCSO-524® and the other components of Lyprinol® are extracted from foods that have been consumed safely for thousands of years. Papers published in the medical journals Inflammopharmacology, Complimentary Therapies in Medicine and Allergie and Immunology reported that Lyprinol® was a more potent anti-inflammatory than prescription drugs and did not have any of the adverse side effects associated with such drugs*.
Speaking plainly
While PCSO-524® has been shown to relieve the pain and swelling of arthritis, it cannot cure arthritis. At this time, there is no cure for arthritis. What PCSO-524® can do is improve a person's quality of life by reducing the severity of the symptoms, without the list of known adverse side effects of prescription drugs. PCSO-524® is a more potent anti-inflammatory than fish oil and, unlike fish oil, it does not cause bleeding. By way of comparison, as an anti-inflammatory PCSO-524® has been shown to be 350 times more potent than fish oil*.
Asthma reduced
PCSO-524® has been shown in a published peer-reviewed clinical trial to reduce the frequency and severity of asthma attacks by as much as 50 per cent*. It should be considered to be a useful adjunct to the asthma management regime prescribed by your doctor, not a replacement. Asthma is caused by an inflammatory response in the airways, which can be triggered by a variety of things that range from allergies to cold air. Because PCSO-524® is a potent natural anti-inflammatory, it modulates the body's inflammatory response and reduces the excessive inflammatory response that leads to asthma*.
Improve exercise performance
The potent anti-inflammatory action of PCSO-524® has been shown in peer-reviewed published trials to improve the breathing of athletes and to reduce the level and duration of post-exercise soreness*. A paper published in the Open Access Journal of Sports Medicine reported that the use of PCSO-524® halved the severity and duration of post-exercise muscle soreness, which is known as delayed-onset muscle scoreness (DOMS). The pain, stiffness and muscle weakness that follows strenuous exercise requires recovery time, which can be between 48 hours to a week. How quickly an athlete can recover to the point that they are able to push the envelope again determines how fit and strong they become. Because PCSO-524® hastens recovery and is completely legal, it can help athletes train harder than someone who is not using it.
Another common problem among people who exercise is exercise-induced bronchoconstriction (EIB), which is also known as exercise-induced asthma (EIA). A paper published in the medical journal Respiratory Medicine reported that when PCSO-524® was used by athletes who experienced EIB there was an average improvement in lung function of 59 per cent. EIB occurs as a result of an inflammatory response in the airways in both asthmatic and non-asthmatic athletes. It can cause a narrowing of the airways, which results in the typical symptoms of EIB, such as wheezing and chest tightness. The deterioration in lung function can happen both during and after exercise. The condition is so common that the International Olympic Committee has estimated that between 10 and 15 per cent of summer Olympians and at least 20 per cent of winter Olympians experience EIB.
Dosage
For the first month take two Lyprinol® capsules in the morning and two in the evening. After the first month you may be able to reduce your intake to one or two capsules per day, for joint care. Everyone's needs are different because of their individual circumstances, so you will have to find what dose works best for you. Because PCSO-524® and the other components of Lyprinol® are derived from foods it is suitable for children, as well as adults. The dose required will vary depending upon the size of the child, but as a general guide we suggest that for children between three and 12 years of age a dose of three capsules per day for the first month and then one or two capsules per day thereafter should be sufficient. While there are no known risks associated with PCSO-524®, for the sake of safety we recommend that a doctor should be consulted before pregnant women, or children younger than one year of age, begin to take Lyprinol®.
Seafood allergies
PCSO-524® and Lyprinol® do not contain the proteins that trigger seafood allergies. There are no known cases of allergic reactions to PCSO-524®.
There is only one PCSO-524®
PCSO-524® is the result of a patented process and, as such, is unique. Were that no so, we would not have been able to patent it. Lyprinol® contains 50mg of PCSO-524®, 100mg of a proprietary oleic acid blend that is derived from olive oil and 0.225mg of d-alpha-tocopherol (natural vitamin E). The active component of Lyprinol®, which is PCSO-524®, is a unique mix of 92 fatty acids that are extracted from the New Zealand green-lipped mussel (Perna canaliculus). What makes PCSO-524® unique is that before the fatty acids are extracted the flesh of the mussel is stabilised to prevent oxidisation. PCSO-524® is the only lipid extract that benefits from the patented stabilisation and extraction process. Without this process, the fatty acids oxidise and become therapeutically useless. This is what distinguishes PCSO-524® and Lyprinol® from other mussel products. There is a mussel powder that also benefits from the patented process, but because the lipids are only 5 per cent of the volume of the powder you would need to take 1,000mg of the powder to equal the efficacy of the 50mg of PCSO-524® that is contained in each Lyprinol® capsule. Decades of published peer-reviewed research have established PCSO-524® and Lyprinol® as the pre-eminent mussel product. Please visit the references page of this website to see a list of the various papers that have been written about the research work conducted on PCSO-524®.
Structure of PCSO-524®
PCSO-524® contains five main lipid classes: sterol esters, triglycerides, free fatty acids, sterols and polar lipids. There are 10 marine sterols in the sterol esters and sterol fractions. It also contains 30 types of essential fatty acids that are mixtures of saturated, monounsaturated and polyunsaturated fatty acids. PCSO-524® contains long-chain omega-3 polyunsaturated fatty acids that are essential for human health. The two main omega-3 polyunsaturated fatty acids in PCSO-524® are eicosapentaenoic acid (EPA) (20 carbon atoms that have five double bonds, which is referred to as 20:5 omega-3); and docosahexaenoic acid (DHA) (22:6 omega-3). PCSO-524 also contains other fatty acids that belong to the omega-3 family. These fatty acids all have four double bonds and have carbon chain lengths of 18, 19 and 20 atoms. They are described as 18:4 omega-3 (18:4n-3); 19:4 omega-3 (19:4n-3); and 20:4 omega-3 (20:4n-3).
The Dosage
Initially take 2-4 capsules per day. 1-2 in the morning and 1-2 at night with meals for approximately 3-6 weeks after which the intake may be reduced to 1-2 capsules per day for joint care. We recommend this product should be taken for at least 8-12 weeks. Do not exceed recommended daily dosage.
The daily level needed to obtain maximum effect can vary for each individual. Your body requires less to achieve full effect, temporary initial discomfort may occur if personal dosage is too high. In this case reduce to 1-2 capsules per day.
CHILDREN: 3 - 12 Years old. 3 capsules daily for 3 weeks and 1 or 2 thereafter with meals.
It is recommended that pregnant women and children under 1 year should only use lyprinol after consultation with a doctor or Health practioner.
Capsules should be consumed with or after meals with water.
Principal Ingredients per 260mg capsule:
Capsule: Gelatin; Sorbitol syrup; Glycerin
|